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Association of hyperuricemia 
and gamma glutamyl transferase 
as a marker of metabolic risk 
in alcohol use disorder
Anna Hernández‑Rubio1, Arantza Sanvisens1, Ferran Bolao2, Clara Pérez‑Mañá3, 
Nuria García‑Marchena1, Carla Fernández‑Prendes4, Alvaro Muñoz5,6 & Roberto Muga1,6*
Excessive alcohol consumption leads to overproduction of urates and renal function plays a critical role 
in serum uric acid levels. We aimed to assess associations of hyperuricemia in patients with alcohol use 
disorder (AUD) and comparable Glomerular Filtration Rate (GFR). A total of 686 patients undergoing 
treatment for AUD between 2013 and 2017 were eligible (77% men); age at admission was 47 years 
[interquartile range (IQR), 40–53 years], age of onset of alcohol consumption was 16 years [IQR, 
16–18 years] and the amount of alcohol consumed was 160 g/day [IQR, 120–240 g/day]. Body Mass 
Index was 24.7 kg/m2 [IQR, 21.9–28.4 kg/m2], eGFR was 105 mL/min/1.73 m2 [IQR, 95.7–113.0 mL], 
9.7% had metabolic syndrome and 23% had advanced liver fibrosis (FIB‑4 > 3.25). Prevalence of 
hyperuricemia was 12.5%. The eGFR‑adjusted multivariate analysis showed that relative to patients 
with GGT ≤ 50, those with GGT between 51 and 300 U/L and those with GGT > 300 U/L were 4.31 (95% 
CI 1.62–11.46) and 10.3 (95% CI 3.50–29.90) times more likely to have hyperuricemia, respectively. Our 
data shows that hyperuricemia in the context of AUD is strongly associated with serum GGT levels and 
suggest an increased cardio‑metabolic risk in this population.
Uric acid is a heterocyclic organic compound synthesized primarily in the liver and small intestine and the final 
product of purine catabolism. Other than purines obtained from food products, the primary endogenous source 
of urates is nucleic acids, specially adenine and  guanine1. The kidney is responsible for removing the majority 
(> 70%) of urates produced  daily2. Excessive alcohol consumption, obesity, metabolic syndrome (MetS) and food 
products with a high concentration of purines or fructose have been associated with  hyperuricemia3.
The estimated prevalence of hyperuricemia in the general population is around 5% and it seems to be much 
higher in hospitalized  patients4,5. There are no universally accepted cut-off levels of serum uric acid (SUA) 
although serum concentrations from 5.0 to 7.5 mg/dL, depending on sex, are considered high. More than two-
thirds of patients with hyperuricemia remain clinically asymptomatic, although the risk of developing gout is 
directly related to SUA  levels3,6.
The mechanisms explaining the pathophysiology of hyperuricemia includes the excessive urate production 
and the reduced renal and extra-renal excretion. The under-excretion of urates is the most frequent etiology 
(90% of cases) of hyperuricemia and it may be classified into primary conditions characterized by a decrease in 
the tubular secretion of urates, or into secondary conditions due to renal failure or other causes such as diabetes, 
alcoholic ketosis and lactic  acidosis2,7.
With respect to the role of ethanol in the SUA levels, excessive alcohol consumption accelerates adenosine 
triphosphate degradation in the liver and increases lactic acid levels in blood during the degradation of etha-
nol. Ethanol also increases the plasma concentration and decreases the urinary excretion of purine bases (i.e. 
hypoxanthine and xanthine) via the acceleration of adenine nucleotide degradation and the possible inhibition 
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of the xanthine dehydrogenase activity. In addition, chronic alcohol consumption might diminish the urinary 
excretion of uric acid due to dehydration and  ketoacidosis8,9.
Hyperuricemia has been associated with an increased risk of cardiometabolic and renal  disease10,11. In addi-
tion, hyperuricemia may increase the risk of hepatic steatosis and gluconeogenesis, which contribute to  MetS12. 
In parallel, patients with alcohol use disorder (AUD) may have a higher risk of cardiovascular risk factors and it 
is estimated that up to 20% of individuals with excessive alcohol consumption have  MetS13,14.
Studies involving moderate alcohol drinkers have shown that SUA levels increase proportionally to the 
amount of alcohol consumed and that this increase is more pronounced among individuals drinking beer or 
 distillates15. However, associations of alcoholic beverages and SUA may be due to the effect of non-alcoholic 
components of beverages (i.e. purine content of beer, antioxidants in wine); these components of alcoholic 
beverages may play a role in the variation of SUA  levels15,16.
It should be noted that the majority of studies on SUA and alcohol consumption have focused on hospitalized 
patients with acute, concurrent illness (i.e. bacterial pneumonia) or in the general  population4,15,17–19. However, 
few studies have taken into account the role of GFR and impaired renal function in SUA levels which may affect 
prevalence and associations of hyperuricemia. The kidney has been recognized as a main regulator of SUA and 
renal urate excretion is determined by the balance of the reabsortion and secretion of  urates2.
We hypothesize that the risk of hyperuricemia in the context of excessive alcohol consumption is multifac-
torial and related to multiple health outcomes which may have implications for clinical practice. We aimed to 
characterize associations of hyperuricemia in AUD patients with comparable GFR.
Methods
This was a cross-sectional study in AUD patients consecutively admitted for detoxification in two hospital units 
in metropolitan Barcelona, Spain: Hospital Universitari de Bellvitge in L’Hospitalet de Llobregat and Hospital 
Universitari Germans Trias i Pujol in Badalona. All patients were consecutively admitted between January 2013 
and November 2017; patients were referred to the Addiction Unit by primary care physicians and specialists in 
addiction medicine at outpatient clinics.
All patients received a diagnosis of alcohol use disorder according to the Diagnostic and Statistical Manual 
of Mental Disorders, 5th Ed (DSM-5)20. Information was collected on socio-demographic variables (sex, age, 
education level and employment). On admission day, patients underwent an interview including questions on 
alcohol consumption such as daily quantity and type of alcohol (beer, wine, liquor/distilled spirits) and age at 
onset of alcohol use. Alcohol consumption was quantified in grams of ethanol per day. Current use of other 
substances (i.e., cocaine) was ascertained by urine detection at admission. Anthropometric data (height and 
weight) were also obtained.
Peripheral blood samples for determining biochemical and hematological parameters were collected the 
second day of admission after overnight fasting. Blood was collected in heparin plasma tubes and transferred to 
the laboratories. Hematological parameters (i.e., hemoglobin, mean corpuscular volume (MCV), platelet count, 
leucocytes, and lymphocytes) and erythrocyte sedimentation rate (ESR) were measured using automated hema-
tological profile analyzers; biochemical parameters [i.e., glucose, urate, albumin, total cholesterol, triglycerides, 
urea, creatinine, aspartate aminotransferase (AST), UA, alanine aminotransferase (ALT), and gamma-glutamyl 
transferase (GGT)] were measured with standard enzymatic methods using multichannel automatic analyzers; 
specifically, the enzymatic colorimetric method was used to assess the SUA level. Overall inter- and intra-assay 
variability was 3.6–12.4%. The clinical chemistry and hematology laboratories of both hospitals complied with 
UNE-EN-ISO9001:2015 standards which accredited them in their respective areas.
Pharmacological treatment during admission included benzodiazepines, vitamin B complex, and other phar-
macotherapy depending on medical co-morbidities, and severity of alcohol withdrawal.
On average, the length of stay was 7 days, and at discharge, patients were advised to attend follow-up visits at 
the outpatient clinic. Other details regarding admission for the treatment of AUD can be found  elsewhere21,22.
A total of 739 patients were admitted during the study period but patients treated with diuretics (n = 36), 
uricosuric agents (n = 12), or both (n = 5) were excluded yielding 686 for analysis presented here. The established 
cut-off value for hyperuricemia was > 7.2 mg/dL in men and > 6 mg/dL in women based on the reference values 
provided by the hospital laboratories.
Renal function was assessed by the estimated glomerular filtration rate (eGFR), calculated using creatinine, 
age, sex and ethnicity through the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI).
Patients were evaluated for liver fibrosis using the FIB-4 index, according to the following equation:
and FIB-4 values > 3.25 indicated advanced liver  fibrosis23.
MetS was defined as Body Mass Index (BMI) > 25 kg/m2 and/or age > 40 years and two or more of the fol-
lowing conditions: serum glucose > 110 mg/dL, triglycerides > 150 mg/dL, HDL-cholesterol < 40 mg/dL in men 
and < 50 mg/dL in women, and blood pressure > 130/85 mmHg or pharmacologic treatment for  hypertension24.
All patients gave written informed consent, and the study design was approved by the Ethics Committee of 
the Hospital Universitari Germans Trias i Pujol (approval number CEXT042013). The methods complied with 
the ethical standards for medical research and the principles of good clinical practice in accordance with the 
World Medical Association’s Declaration of Helsinki.
Statistical analysis. Descriptive statistics were expressed as median (interquartile range (IQR)) for quanti-
tative variables and as absolute frequencies and percentages for qualitative variables.
FIB4 =
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We used the Chi-square test for qualitative variables and Student’s t test or Mann–Whitney U test in quantita-
tive variables to analyze differences in patients with and without hyperuricemia. Correlations were determined 
using Pearson’s correlation coefficient.
Logistic regression models were applied to establish factors associated with hyperuricemia. Sociodemographic 
variables (age and sex), ESR, albumin and GGT levels, FIB-4, and MetS were analyzed after adjusting for eGFR; 
for these analysis the eGFR was considered a continuous variable and GGT levels were stratified as ≤ 50 U/L, 
51–300 U/L, > 300 U/L, altered ESR was defined as > 20 mm and hypoalbuminaemia < 35 g/L.
The covariates included in the multivariate analysis were those that were found to be statistically significant 
in the eGFR-adjusted univariate analysis.
Sensitivity analyses of logistic regression models were performed to further analyze associations of hyper-
uricemia when using different SUA cut-offs. Lower cut-off values (6.0 mg/dL for men and 5.0 mg/dL for women), 
higher cut-off values (8.0 mg/dL for men and 6.5 mg/dL for women), and a single cut-off point (7.0 mg/dL for 
both sexes) were used.
P values < 0.05 were considered statistically significant. Statistical analyses were performed using Stata soft-
ware (version 11.1, College Station, Texas, USA).
Results
A total of 686 patients (77% men) were eligible, with a median age of 47 years [interquartile range (IQR), 
40–53 years]. The age of onset of alcohol consumption was 16 years [IQR, 16–18 years] and the amount of alco-
hol consumed was 160 g/day [IQR, 120–240 g/day]. BMI was 24.7 kg/m2 [IQR, 21.9–28.4 kg/m2], eGFR was 
105 mL/min/1.73 m2 [IQR, 95.7–113.0 mL], 9.7% had MetS and 23% had advanced liver fibrosis (FIB-4 > 3.25). 
The prevalence of hyperuricemia was 12.5%.
Sociodemographic characteristics and data on the consumption of alcohol and other substances in patients 
with and without hyperuricemia are shown in Table 1. Patients presenting with hyperuricemia were older than 
those without hyperuricemia (mean 48.6 vs. 46.4 years, P = 0.041). Sex, educational level, employment and 
characteristics related to alcohol consumption and other substances were similar in those with and without 
hyperuricemia.
The results of laboratory parameters upon admission are shown in Table 2. Patients with hyperuricemia 
showed higher prevalence of elevated ESR (P = 0.010), elevated GGT (P < 0.001), and lower eGFR (P = 0.001) than 
those without hyperuricemia. Specifically, the probability of presenting with hyperuricemia increased 1.5-fold for 
each decrease of 10 mL/min/1.73 m2 in the eGFR. A total of 24 (30.8%) patients among those with hyperurice-
mia and 121 (22%) among those without hyperuricemia had advanced liver fibrosis (FIB-4 > 3.25) (P = 0.087).
Figure 1 shows the negative correlation between SUA and eGFR. Specifically, for each decrease of 10 mL/
min/1.73 m2 in the eGFR, SUA increased by 0.24 mg/dL (r = − 0.232, P < 0.001).
The eGFR-adjusted, logistic regression models are shown in Table 3. Elevated ESR, increased GGT levels, and 
advanced liver fibrosis were significant predictors of hyperuricemia in the eGFR-adjusted univariate analysis. 
Multivariate analysis showed that serum GGT was the only independent predictor of hyperuricemia (P < 0.001). 
Specifically, relative to patients with GGT ≤ 50, those with GGT between 51 and 300 and those with GGT > 300 
U/L were 4.31 (95% CI 1.62–11.46) and 10.3 (95% CI 3.50–29.90) times more likely to have hiperuricemia, 
respectively. The drastic differences between the odds ratios associated with FIB-4 obtained from univariate 
and multivariate logistic regression are due to strong confounding with GGT. Specifically, among those with 
FIB-4 ≤ 3.25, 31.9%, 53.2% and 14.9% had GGT ≤ 50, 51 < GGT ≤ 300 and GGT > 300 U/L, respectively; and in 
contrast, among those with FIB-4 > 3.25, the great majority had GGT > 300 with 2.1%, 30.6% and 67.4% having 
GGT ≤ 50, 51 < GGT ≤ 300 and GGT > 300 U/L, respectively. Likewise, among those with ESR ≤ 20 mm, 28.7%, 
49.4% and 21.9% had GGT ≤ 50, 51 < GGT ≤ 300 and GGT > 300 U/L, respectively; and in contrast, among those 
with ESR > 20 mm, 17.2%, 43.3% and 39.5% had GGT ≤ 50, 51 < GGT ≤ 300 and GGT > 300 U/L, respectively.
The results of sensitivity analyses using different cut-off values for SUA were consistent with those presented 
here.
Discussion
The role of excessive alcohol consumption in the risk of hyperuricemia/gout and metabolic complications is well 
known. However, few studies have analyzed the determinants of hyperuricemia in patients with eGFR-adjusted 
(i.e., comparable renal function). The kidney is a key regulator of circulating uric acid levels by reabsorbing 90% 
of filtered urate and results from this large case-series indicates that one in eight patients with AUD had hyper-
uricemia. In addition, prevalence would reach 14% if we had included patients who were treated with uricosuric 
agents or diuretics upon admission; such similar prevalence of hyperuricemia has been reported in individuals 
with heavy alcohol  consumption19,25. More important, our data indicates a strong dose–response relationship 
between serum GGT and SUA levels after adjusting for potential confounders (i.e., increased GGT serum levels 
independently contributed to increases in SUA levels) and this finding may have implications in clinical practice 
and public health interventions. Studies have shown the role of serum GGT as a surrogate of oxidative  stress26–28 
and pointed out that both SUA and GGT are markers of cardio-metabolic  risk28–32. In this sense, serum GGT 
is a marker of hepatic intracellular triglyceride accumulation that has been linked to obesity, insulin resistance, 
 atherosclerosis33,34, and hyperuricemia regardless of alcohol  consumption35,36.
Serum GGT may be a contributing factor for hyperuricemia through oxidative stress and insulin resistance. 
Specifically, serum GGT is associated with hepatic insulin resistance, which in turn is correlated with hyperurice-
mia due to a reduction in urate  excretion12,37. On the other hand, GGT plays a critical role in the metabolism 
of glutathione, a key antioxidant in humans, and there is a correlation between elevated GGT serum levels and 
oxidative stress leading to  steatohepatitis30,38. Furthermore, uric acid itself promotes oxidative stress in adipocytes 
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by increasing monocyte chemotactic protein-1 and decreasing  adiponectin39. In addition, the pro-oxidant action 
of uric acid is also related to the accumulation of triglycerides in the liver (i.e. steatohepatitis)12,37.
Two studies in the general population have analyzed the connection between serum GGT and SUA. One study 
evaluated normotensive individuals free of liver, kidney, and metabolic diseases and found a positive correlation 
between serum GGT and  urate28. The other analyzed the general Japanese population and demonstrated a strong 
correlation between the two serum markers in both men and  women40.
To the best of our knowledge, the present study is the first to report serum GGT as an independent contribut-
ing factor for hyperuricemia in AUD.
In this study, there were no significant differences in prevalence of hyperuricemia according to the amount 
and type of alcoholic beverage. A population study based on the US Third National Health and Nutritional 
Examination Survey (NHANES III) found that SUA levels increased as total alcohol intake  increased15. With 
regard to the type of alcoholic beverage, several studies have shown that, in contrast to wine, the consumption of 
beer and spirits is related to higher SUA levels and to an increased risk of  gout15,41. Notwithstanding, the absence 
of significant associations between hyperuricemia and the amount and type of alcohol consumed in our study 
population might be due to the large amount of alcohol ingested daily. In this respect, few studies have analyzed 
the association between SUA levels and the drinking pattern in the context of AUD. A population study in Taiwan 
(2017) involving 11,675 people with alcohol-related diseases, including alcohol dependence, suggested a positive 
relationship between long-term alcohol dependence and gout  risk17.
Table 1.  Characteristics of patients with and without hyperuricemia admitted for the treatment of AUD in 




N = 600 P value
Sociodemographic
Women, n (%) 20 (23.3) 136 (22.7) 0.903




  Unemployed, n (%) 30 (38.5) 228 (49.2)
  Employed, n (%) 22 (28.2) 141 (30.4)




  Illiterate, n (%) 4 (5.4) 18 (3.5)
  Primary, n (%) 14 (18.9) 164 (32.3)
  Secondary, n (%) 45 (60.8) 271 (53.4)
  University, n (%) 11 (14.9) 54 (10.6)
Alcohol and other substances
Age of onset alcohol consumption
 Non-missing 79 600
0.268
 Median (IQR) 16 (16–18) 16 (16–18)
Antecedent of AUD treatment
 Non-missing 85 543
0.998
 n (%) 62 (72.9) 396 (72.9)
Amount of alcohol consumption (g/day)
 Non-missing 81 558
0.477








 n (%) 1 (1.3) 14 (2.6)
Type of alcoholic beverage
 Non-missing 68 426
0.958
  Only wine, n (%) 6 (8.8) 45 (10.6)
  Only beer, n (%) 25 (36.8) 145 (34.0)
  Only liquor and/or distilled, n (%) 7 (10.3) 45 (10.6)
  ≥ two types of alcohol, n (%) 30 (44.1) 191 (44.8)
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 Median (IQR) 28.7 (25.1–32.7) 24.2 (21.8–32.7)
Haematology
Platelet count (× 109 L)
 Non-missing 86 596
0.045












 Median (IQR) 10 (5–27) 8 (4–17)

















 Median (IQR) 40 (36–43) 39.8 (37–42)
















 Median (IQR) 211.8 (102–702.6) 102 (42–286)
 ≤ 50, n (%) 8 (9.4) 172 (29.0)
< 0.001 51–300, n (%) 42 (49.4) 279 (47.1)
 > 300, n (%) 35 (41.2) 141 (23.8)
SUA (mg/dL), 
Median (IQR) 7.8 (7.4–8.5) 4.9 (4.1–5.7) < 0.001
Comorbidity
Advanced liver fibrosis, FIB-4 > 3.25
 Non-missing 78 549
0.087




 n (%) 11 (13.6) 52 (9.1)
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The present study has limitations that should be mentioned. First of all, variables related to the risk factors 
for hyperuricemia such as dietary habits were not available; in this sense, the link between fructose-rich bever-
ages and purine-rich foods with hyperuricemia/gout is well  known6. Moreover, some cases of hyperuricemia 
could be hereditary due to inborn errors of purine and pyrimidine  metabolism42; in addition, familial and twin 
studies estimating the heritability of SUA alterations suggest that genetic factors may explain up to 25–60% of 
the variability in SUA  levels18,43. Finally, the cross-sectional design of this study did not allow the establishment 
of causal relationships.
In conclusion, hyperuricemia was found to be relatively common in patients seeking treatment of AUD and 
closely linked to GGT which suggest an increased cardiometabolic risk in this population.
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